COVID-19疫苗犹豫与感知的接种后不良事件:一项横断面调查的结果
2023年9月在魁北克对至少接种一剂COVID-19疫苗的成年人开展网络调查,8419名受访者中46.7%报告曾出现不良事件;接种前非常犹豫者报告严重不良事件的比例高于不犹豫者(25.0% vs 3.4%,p<0.001)。疫苗犹豫可能影响自报不良事件及其感知严重程度,透明且有针对性的沟通可能有益。
要点
- 8419名接种者中46.7%报告曾出现不良事件,最常见为疲劳或不适(20.7%)。
- 接种前非常犹豫者严重不良事件报告率25.0% vs 不犹豫者3.4%(p<0.001)。
- 自报不良事件妨碍活动(aOR=4.87)与总体疫苗犹豫(aOR=4.94)与未来接种其他疫苗意愿降低显著相关。
核心结论
- 疫苗犹豫可能影响自报不良事件及其感知严重程度。
- 透明且有针对性的沟通,在解释不良事件的同时强调减轻这些影响的策略,可能有益。
- 研究结果对药物警戒也有启示。
研究设计与样本
- 2023年9月对魁北克至少接种一剂COVID-19疫苗的成年人开展网络调查。
- 参与者报告接种前疫苗犹豫程度及接种后不良事件体验,并标注其认为由接种所致症状的严重程度,同时询问未来接种其他疫苗的意愿。
- 两名编码者对报告的不良事件进行定性内容分析(N=3808),并开展描述性和多变量逻辑回归分析。
主要发现
- 8419名已接种受访者中,46.7%报告曾经历不良事件。
- 最常见报告依次为疲劳或不适(20.7%)、注射部位异常(17.3%)、肌肉骨骼疼痛(11.2%)、头痛(11.0%)和发热(10.6%)。
- 接种前非常犹豫者报告严重不良事件的比例高于不犹豫者(25.0% vs 3.4%,p<0.001)。
- 考虑所有严重程度的不良事件时,非常犹豫者报告比例仍高于不犹豫者(68.7% vs 36.9%,p<0.001)。
- 多变量分析中,较低年龄(aOR=0.98)、女性(aOR=1.31)、较高教育水平(大学学位 vs 高中或以下,aOR=1.56)、总体疫苗犹豫(aOR=1.69 vs 不犹豫或较少犹豫)与自报不良事件显著相关(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In Quebec, COVID-19 vaccine uptake among adults was high for the first two doses but decreased for the subsequent booster doses. This study assesses the relationships between attitudes towards vaccination and self-reported experience and severity of adverse events following immunization (AEFIs). METHODS: A web survey of Quebec adults who received at least one dose of the COVID-19 vaccine was conducted in September 2023. Participants share their level of vaccine hesitancy before vaccination and their experience with AEFIs after receiving a dose. Participants were asked to note the severity of the symptoms they believed were due to vaccination. Intention to receive other vaccines in the future was questioned. Two coders performed a qualitative content analysis on reported AEFIs (N = 3808). Descriptive and multivariate logistic regression analyses were performed. RESULTS: Among the 8419 vaccinated respondents, 46.7 % reported having experienced AEFIs. Fatigue or malaise (20.7 %), injection site disorder (17.3 %), musculoskeletal pain (11.2 %), headache (11.0 %), and fever (10.6 %) were the most commonly reported, respectively. Respondents who were very hesitant before the COVID-19 vaccine reported more frequently having a severe AEFI compared to those who were not hesitant (25.0 % vs 3.4 % =, p < 0.001). This affirmation stays true when all severity of adverse events are considered (68.7 % vs 36.9 %) (p < 0.001). Younger age (aOR = 0.98), being a female (aOR = 1.31), a higher education level (University degree aOR = 1.56 vs high school or less), being vaccine-hesitant in general (aOR = 1.69 vs non or less hesitant) were significantly associated (p < 0.001) with self-reported AEFIs in multivariate analysis. Self-reported AEFIs that prevented doing activities (aOR = 4.87) and being vaccine-hesitant in general (aOR = 4.94) were significantly associated with reduced intention to receive other vaccines in the future. CONCLUSION: Vaccine hesitancy could influence self-reported AEFIs and their perceived severity. Transparent and tailored communication explaining AEFIs while emphasizing strategies to mitigate these effects could helpful. Our findings also have implications for pharmacovigilance. 301 mots.
引用
- Dionne M, Sauvageau C, Ward JK, et al. COVID-19 vaccine hesitancy and perceived post-vaccination adverse event: Findings from a cross-sectional survey. Vaccine. 2025. PMID: 40690852. doi:10.1016/j.vaccine.2025.127529
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。